title: Clinical equivalence of conventional OnabotulinumtoxinA (900 KDa) and IncobotulinumtoxinA (neurotoxin free from complexing proteins - 150 KDa): 2012 multidisciplinary French consensus in aesthetics.
abstract: Botulinum neurotoxins are the most popular non-surgical treatments for aesthetic indications, but there is uncertainty about whether certain formulations are comparable in efficacy and safety and can be substituted for one another by a simple one to one dose conversion ratio. An expert panel of French practitioners was convened to establish a consensus on the clinical equivalence in efficacy and safety of OnabotulinumtoxinA (900 KDa) and IncobotulinumtoxinA (neurotoxin free from complexing proteins - 150 KDa). The consensus was divided into three sections incorporating a biological, bibliographic and clinical analysis of the two toxins. This included a review of the published data that have directly compared the two toxins for aesthetic indications and a survey of the panel's extensive clinical experience with the two toxins in terms of efficacy and safety. All panel members reviewed and endorsed the content of each section. Among this expert panel of French aesthetic physicians and biologists there was consensus that OnabotulinumtoxinA and IncobotulinumtoxinA are clinically equivalent in terms of efficacy and safety, and that a switch from one drug to the other can be made using a simple 1:1 conversion ratio.
authors.forename: Bernard
authors.initials: B
authors.lastname: Poulain
authors.forename: Patrick
authors.initials: P
authors.lastname: Trevidic
authors.forename: Micheline
authors.initials: M
authors.lastname: Clave
authors.forename: Claude
authors.initials: C
authors.lastname: Aharoni
authors.forename: Martine
authors.initials: M
authors.lastname: Baspeyras
authors.forename: Patrick
authors.initials: P
authors.lastname: Bui
authors.forename: Hugues
authors.initials: H
authors.lastname: Cartier
authors.forename: Marie-Helene
authors.initials: MH
authors.lastname: Charavel
authors.forename: Pierre
authors.initials: P
authors.lastname: Coulon
authors.forename: Serge
authors.initials: S
authors.lastname: Dahan
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Dallara
authors.forename: Denis
authors.initials: D
authors.lastname: Delonca
authors.forename: Laurent
authors.initials: L
authors.lastname: Dumas
authors.forename: Eric
authors.initials: E
authors.lastname: Essayagh
authors.forename: Olivier
authors.initials: O
authors.lastname: Galatoire
authors.forename: Nicolas
authors.initials: N
authors.lastname: Georgieu
authors.forename: Yann
authors.initials: Y
authors.lastname: Grangier
authors.forename: Philippe
authors.initials: P
authors.lastname: Humbert
authors.forename: Anne
authors.initials: A
authors.lastname: Le Pillouer-Prost
authors.forename: Alain
authors.initials: A
authors.lastname: Mojallal
mesh_terms: D019274:Botulinum Toxins, Type A / Q000008:administration & dosage* / Q000009:adverse effects; D003357:Cosmetic Techniques; D005602:France; D006801:Humans; D009465:Neuromuscular Agents / Q000008:administration & dosage / Q000009:adverse effects; D013810:Therapeutic Equivalency
chemical_list: D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A; C545476:incobotulinumtoxinA